MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION
DOI10.1081/BIP-100101181zbMATH Open0955.62115OpenAlexW2074887877WikidataQ52211232 ScholiaQ52211232MaRDI QIDQ4512728FDOQ4512728
David Melnychuk, Elizabeth Eisenhauer, Janet Dancey, Benny Zee
Publication date: 27 February 2001
Published in: Journal of Biopharmaceutical Statistics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1081/bip-100101181
Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical analysis (62L10)
Cites Work
- Designs for Group Sequential Phase II Clinical Trials
- One-Sample Multiple Testing Procedure for Phase II Clinical Trials
- Bivariate Sequential Designs for Phase II Trials
- A Bayesian Approach to the Design of Phase II Clinical Trials
- Designs for Phase II Trials Allowing for a Trade-Off between Response and Toxicity
- Practical Bayesian Guidelines for Phase IIB Clinical Trials
Cited In (5)
- Testing Statistical Hypotheses on Stochastic Ordering of Discrete Distributions
- Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control
- Randomized phase II cancer clinical trials
- Design efficiency in dose finding studies
- Boundary Crossing Random Walks, Clinical Trials, and Multinomial Sequential Estimation
Recommendations
- Randomized phase II cancer clinical trials 👍 👎
- Optimal adaptive two-stage designs for phase II cancer clinical trials 👍 👎
- Improving the Flexibility and Efficiency of Phase II Designs for Oncology Trials 👍 👎
- Adaptive Two-Stage Designs for Single-Arm Phase IIA Cancer Clinical Trials 👍 👎
- Two-stage design for phase II oncology trials with relaxed futility stopping 👍 👎
This page was built for publication: MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4512728)
